C017: ReFacto Biosimilar Stable Cell Line (CHO)
The yield of ReFacto biosimilar from the CHO stable cell line was above 60 IU/mL in a 50 liter manufacturing.
BP003051: Biotinylated Recombinant SARS-CoV-2 Spike RBD-His-Avi (S1 RBD)
Source: mammalian cells.
Activity: Immobilized biotinylated recombinant SARS-CoV-2 Spike RBD-His-Avi protein at 1 ug/ml (100 ul/well). Dose response curve for the recombinant human ACE2-Fc fusion protein with the EC50 of 100 ng/ml determined by ELISA.
Purity: > 95% by PAGE under reduced condition, and SEC-HPLC.BP003082: Recombinant Human CD319 / CRACC / SLAMF7 Protein
Source: mammalian cells.
Purity: > 95% by Bis-Tris PAGE and HPLC.BP003082: Recombinant Human CD319 / CRACC / SLAMF7 Protein
Source: mammalian cells.
Purity: > 95% by Bis-Tris PAGE and HPLC.BP003082: Recombinant Human CD319 / CRACC / SLAMF7 Protein
Source: mammalian cells.
Purity: > 95% by Bis-Tris PAGE and HPLC.BP000339-GD15: Recombinant Human Chorionic Gonadotropin (hCG)
Source: CHO-derived.
The hCG α/β activity was determined to be 25,000 IU/mg.
Purity > 97% by SDS-PAGE under reducing conditions and visualized by silver stain, and 97% by SEC-HPLC.BP002388-Z53: Recombinant Human Cellular tumor antigen p53 (p53) Protein
Source: Baculovirus, SF9 insect cells-derived.
Bioactivity test: 1 unit equals 1 nanogram of purified protein. 10 unit is sufficient for a gel mobility shift assay in a 20 ul reaction; 50 units are sufficient for reconstituted transcription assay and 100 units are sufficient for a protein-protein interaction assay.
Purity: > 95%, by SDS-PAGE.
Endotoxin Level: < 1.0 EU per 1 ug of the protein by the LAL method.BP000035-GD9: Recombinant Human FSH α/β Protein
Source: CHO cell-derived.
The FSH α/β activity is measured in a human FSH receptor transfected HEK 293 cells. The ED50 for this effect is 0.1-0.4 ng/ml.
Endotoxin Level: <1.0 EU per 1 ug of the protein by the LAL method.
Purity > 95%, by SDS-PAGE under reducing conditions and visualized by silver stain.BP001573-K0104: Recombinant Human PAK1 Kinase Domain (PAK1KD) Enzyme
Source: E. coli-derived.
Specific activity: 32,638 pmoles/min/ug. Analysis of enzymatic activity was performed according to the Zlyte assay protocol (Invitrogen).
Applications: Enzymatic studies, inhibitor screen, and selectivity profiling; High concentration available for crystallization.BP001574-K0105: Recombinant Human PAK2 kinase domain (PAK2KD) Enzyme
Source: E. coli-derived.
Specific activity: 85,806 pmoles/min/ug. Analysis of enzymatic activity was performed according to the Zlyte assay protocol (Invitrogen).
Applications: Enzymatic studies, inhibitor screen, and selectivity profiling; High concentration available for crystallization.